Vital Signs: How Medtech Companies Can Heal the Aches and Pains of Modern Healthcare Systems

Posted by Will Randall on November 15, 2018

Hospital spending has grown 15% and patient admissions are up 20% since 2009. Despite some efficiency gains, the provider financial deficit is large and growing, and patients are waiting longer than ever before for treatment in a system stretched to capacity. Sound familiar?


>
Read More

Medtech Companies Need to be Solutions-Oriented, not Product-Driven

Posted by Rohan Agni on October 18, 2018

The vice president of supply chain at a top IDN system recently told me, “In medtech, there is no evidence-based information whatsoever that one manufacturer is better than another. Take CRM, for example. There are three top players, but there’s no evidence that any one pacemaker is better than the others."


>
Read More

Analyzing Medtronic’s Move: Put Your Money Where Your Outcomes Are

Posted by Will Randall on March 27, 2018

As the healthcare industry continues to embrace value-based care, medtech companies are increasingly looking to go beyond their traditional product-and-price business models and explore new ways to demonstrate the value of their offerings to providers. In a recent Wall Street Journal article, Medtronic Chairman and CEO Omar Ishrak gives insight into the leadership mindset of one company that’s executing a value-based care (VBC) vision that aligns with its existing portfolio of products and services.


>
Read More

The Shift From Sales Excellence to Marketing Excellence

Posted by Matt Scheitlin on October 6, 2017

Ten years ago, having a sales force effectiveness center of excellence was unique in the medtech industry but is now a cornerstone of every high-performing organization. Now, marketing excellence is the next great differentiator for medtech commercial operations.


>
Read More

Are Internal Challenges Preventing Your Organization From Demonstrating Value?

Posted by Will Randall on September 15, 2017

Large-scale mergers and acquisitions continue to be a trend shaping the medtech industry. This year alone, two multi-billion dollar acquisitions (Abbott/St. Jude Medical is complete and Becton Dickinson/C.R. Bard is pending) aimed to create large medtech organizations with broad portfolios and businesses spanning many therapy areas and hospital departments. Several other billion-dollar deals have also made headlines in recent months. These combined entities should be in a strong position to articulate a portfolio value proposition that can help providers improve the quality and outcomes of patient care.


>
Read More